Metoclopramide Orbit Pharma (Metoclopramide Hydrochloride)

Metoclopramide works by blocking dopamine D2 receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This blockade increases acetylcholine release, which stimulates smooth‑muscle contraction and speeds gastric emptying, while also providing a central anti‑emetic effect.

The specific dose of Metoclopramide is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal function. Typical dosing regimens range from low‑dose intermittent injections to higher‑dose continuous infusions, but the exact regimen must be set by a qualified health professional.

Safety data for Metoclopramide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a healthcare provider after a careful risk‑benefit assessment.

To place an order, submit an enquiry on the Metoclopramide Orbit Pharma product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Metoclopramide differs from many anti‑emetics by combining central dopamine antagonism with peripheral pro‑kinetic activity, which can be advantageous in conditions like gastroparesis. Compared with pure dopamine antagonists or serotonin antagonists, it may offer faster gastric emptying but carries a higher risk of extrapyramidal side effects, especially with prolonged use.

Metoclopramide injectable solution should be stored at temperatures below 25 °C, protected from moisture and light, and kept in its original packaging until use. Do not freeze the product. Follow standard aseptic techniques when preparing the injection to maintain sterility.

Metoclopramide is administered by intramuscular or intravenous injection. The route and rate of administration are selected by the prescriber, who may give a single dose, repeated doses, or a continuous infusion depending on the clinical situation and therapeutic goal.

Serious risks include extrapyramidal reactions such as dystonia or akathisia, tardive dyskinesia with long‑term use, neuroleptic malignant syndrome, severe allergic reactions, and cardiac arrhythmias. Patients should be monitored for any new movement disorders, skin reactions, or cardiac symptoms, and therapy should be discontinued if serious adverse events occur.

Metoclopramide is contraindicated in patients with known hypersensitivity to the drug, those with pheochromocytoma, and individuals with a history of severe extrapyramidal reactions. Caution is also advised for patients with gastrointestinal obstruction, perforation, or hemorrhage, as well as for those taking interacting medications listed under major interactions.